

The 2023-2028 Outlook for Hydroxyurea Sickle Cell Disease Treatments in India

https://marketpublishers.com/r/2BF449B605D9EN.html

Date: September 2022 Pages: 404 Price: US\$ 595.00 (Single User License) ID: 2BF449B605D9EN

Abstracts

This study covers the latent demand outlook for hydroxyurea sickle cell disease treatments across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-?-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for hydroxyurea sickle cell disease treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of hydroxyurea sickle cell disease treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Acceleron Pharma, Alnylam Pharmaceuticals, Arena Pharmaceuticals, AstraZeneca, Baxter International, bluebird bio, Bristol-Myers Squibb, Eli Lilly and Company, Emmaus Life Sciences, Global Blood Therapeutics, Novartis, Pfizer, and Sangamo Therapeutics. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars



are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).



Contents

1 INTRODUCTION

1.1 OVERVIEW
1.2 WHAT IS LATENT DEMAND AND THE P.I.E.?
1.3 THE METHODOLOGY
1.3.1 STEP 1. PRODUCT DEFINITION AND DATA COLLECTION
1.3.2 STEP 2. FILTERING AND SMOOTHING
1.3.3 STEP 3. FILLING IN MISSING VALUES
1.3.4 STEP 4. VARYING PARAMETER, NON-LINEAR ESTIMATION
1.3.5 STEP 5. FIXED-PARAMETER LINEAR ESTIMATION
1.3.6 STEP 6. AGGREGATION AND BENCHMARKING
1.4 FREQUENTLY ASKED QUESTIONS (FAQ)
1.4.1 CATEGORY DEFINITION
1.4.2 UNITS
1.4.3 METHODOLOGY

2 SUMMARY OF FINDINGS

- 2.1 LATENT DEMAND IN INDIA
- 2.2 TOP 100 CITIES SORTED BY RANK
- 2.3 LATENT DEMAND BY YEAR IN INDIA

3 ANDAMAN & NICOBAR ISLANDS

3.1 LATENT DEMAND BY YEAR - ANDAMAN & NICOBAR ISLANDS3.2 CITIES SORTED BY RANK - ANDAMAN & NICOBAR ISLANDS3.3 CITIES SORTED BY DISTRICT - ANDAMAN & NICOBAR ISLANDS

4 ANDHRA PRADESH

4.1 LATENT DEMAND BY YEAR - ANDHRA PRADESH4.2 CITIES SORTED BY RANK - ANDHRA PRADESH4.3 CITIES SORTED BY DISTRICT - ANDHRA PRADESH

5 ARUNACHAL PRADESH

5.1 LATENT DEMAND BY YEAR - ARUNACHAL PRADESH

The 2023-2028 Outlook for Hydroxyurea Sickle Cell Disease Treatments in India



5.2 CITIES SORTED BY RANK - ARUNACHAL PRADESH 5.3 CITIES SORTED BY DISTRICT - ARUNACHAL PRADESH

6 ASSAM

6.1 LATENT DEMAND BY YEAR - ASSAM6.2 CITIES SORTED BY RANK - ASSAM6.3 CITIES SORTED BY DISTRICT - ASSAM

7 BIHAR

7.1 LATENT DEMAND BY YEAR - BIHAR7.2 CITIES SORTED BY RANK - BIHAR7.3 CITIES SORTED BY DISTRICT - BIHAR

8 CHANDIGARH

8.1 LATENT DEMAND BY YEAR - CHANDIGARH8.2 CITIES SORTED BY RANK - CHANDIGARH8.3 CITIES SORTED BY DISTRICT - CHANDIGARH

9 CHHATTISGARH

9.1 LATENT DEMAND BY YEAR - CHHATTISGARH9.2 CITIES SORTED BY RANK - CHHATTISGARH9.3 CITIES SORTED BY DISTRICT - CHHATTISGARH

10 DADRA & NAGAR HAVELI

10.1 LATENT DEMAND BY YEAR - DADRA & NAGAR HAVELI10.2 CITIES SORTED BY RANK - DADRA & NAGAR HAVELI10.3 CITIES SORTED BY DISTRICT - DADRA & NAGAR HAVELI

11 DAMAN & DIU

11.1 LATENT DEMAND BY YEAR - DAMAN & DIU11.2 CITIES SORTED BY RANK - DAMAN & DIU11.3 CITIES SORTED BY DISTRICT - DAMAN & DIU



12 DELHI

12.1 LATENT DEMAND BY YEAR - DELHI12.2 CITIES SORTED BY RANK - DELHI12.3 CITIES SORTED BY DISTRICT - DELHI

13 GOA

13.1 LATENT DEMAND BY YEAR - GOA13.2 CITIES SORTED BY RANK - GOA13.3 CITIES SORTED BY DISTRICT - GOA

14 GUJARAT

14.1 LATENT DEMAND BY YEAR - GUJARAT14.2 CITIES SORTED BY RANK - GUJARAT14.3 CITIES SORTED BY DISTRICT - GUJARAT

15 HARYANA

15.1 LATENT DEMAND BY YEAR - HARYANA15.2 CITIES SORTED BY RANK - HARYANA15.3 CITIES SORTED BY DISTRICT - HARYANA

16 HIMACHAL PRADESH

16.1 LATENT DEMAND BY YEAR - HIMACHAL PRADESH16.2 CITIES SORTED BY RANK - HIMACHAL PRADESH16.3 CITIES SORTED BY DISTRICT - HIMACHAL PRADESH

17 JAMMU & KASHMIR

17.1 LATENT DEMAND BY YEAR - JAMMU & KASHMIR17.2 CITIES SORTED BY RANK - JAMMU & KASHMIR17.3 CITIES SORTED BY DISTRICT - JAMMU & KASHMIR

18 JHARKHAND

18.1 LATENT DEMAND BY YEAR - JHARKHAND

The 2023-2028 Outlook for Hydroxyurea Sickle Cell Disease Treatments in India



18.2 CITIES SORTED BY RANK - JHARKHAND 18.3 CITIES SORTED BY DISTRICT - JHARKHAND

19 KARNATAKA

19.1 LATENT DEMAND BY YEAR - KARNATAKA19.2 CITIES SORTED BY RANK - KARNATAKA19.3 CITIES SORTED BY DISTRICT - KARNATAKA

20 KERALA

20.1 LATENT DEMAND BY YEAR - KERALA 20.2 CITIES SORTED BY RANK - KERALA 20.3 CITIES SORTED BY DISTRICT - KERALA

21 LAKSHADWEEP

21.1 LATENT DEMAND BY YEAR - LAKSHADWEEP21.2 CITIES SORTED BY RANK - LAKSHADWEEP21.3 CITIES SORTED BY DISTRICT - LAKSHADWEEP

22 MADHYA PRADESH

22.1 LATENT DEMAND BY YEAR - MADHYA PRADESH22.2 CITIES SORTED BY RANK - MADHYA PRADESH22.3 CITIES SORTED BY DISTRICT - MADHYA PRADESH

23 MAHARASHTRA

23.1 LATENT DEMAND BY YEAR - MAHARASHTRA23.2 CITIES SORTED BY RANK - MAHARASHTRA23.3 CITIES SORTED BY DISTRICT - MAHARASHTRA

24 MANIPUR

24.1 LATENT DEMAND BY YEAR - MANIPUR24.2 CITIES SORTED BY RANK - MANIPUR24.3 CITIES SORTED BY DISTRICT - MANIPUR



25 MEGHALAYA

25.1 LATENT DEMAND BY YEAR - MEGHALAYA25.2 CITIES SORTED BY RANK - MEGHALAYA25.3 CITIES SORTED BY DISTRICT - MEGHALAYA

26 MIZORAM

26.1 LATENT DEMAND BY YEAR - MIZORAM26.2 CITIES SORTED BY RANK - MIZORAM26.3 CITIES SORTED BY DISTRICT - MIZORAM

27 NAGALAND

27.1 LATENT DEMAND BY YEAR - NAGALAND27.2 CITIES SORTED BY RANK - NAGALAND27.3 CITIES SORTED BY DISTRICT - NAGALAND

28 ORISSA

28.1 LATENT DEMAND BY YEAR - ORISSA28.2 CITIES SORTED BY RANK - ORISSA28.3 CITIES SORTED BY DISTRICT - ORISSA

29 PONDICHERRY

29.1 LATENT DEMAND BY YEAR - PONDICHERRY29.2 CITIES SORTED BY RANK - PONDICHERRY29.3 CITIES SORTED BY DISTRICT - PONDICHERRY

30 PUNJAB

30.1 LATENT DEMAND BY YEAR - PUNJAB30.2 CITIES SORTED BY RANK - PUNJAB30.3 CITIES SORTED BY DISTRICT - PUNJAB

31 RAJASTHAN

31.1 LATENT DEMAND BY YEAR - RAJASTHAN

The 2023-2028 Outlook for Hydroxyurea Sickle Cell Disease Treatments in India



31.2 CITIES SORTED BY RANK - RAJASTHAN 31.3 CITIES SORTED BY DISTRICT - RAJASTHAN

32 SIKKIM

32.1 LATENT DEMAND BY YEAR - SIKKIM32.2 CITIES SORTED BY RANK - SIKKIM32.3 CITIES SORTED BY DISTRICT - SIKKIM

33 TAMIL NADU

33.1 LATENT DEMAND BY YEAR - TAMIL NADU33.2 CITIES SORTED BY RANK - TAMIL NADU33.3 CITIES SORTED BY DISTRICT - TAMIL NADU

34 TRIPURA

34.1 LATENT DEMAND BY YEAR - TRIPURA34.2 CITIES SORTED BY RANK - TRIPURA34.3 CITIES SORTED BY DISTRICT - TRIPURA

35 UTTAR PRADESH

35.1 LATENT DEMAND BY YEAR - UTTAR PRADESH35.2 CITIES SORTED BY RANK - UTTAR PRADESH35.3 CITIES SORTED BY DISTRICT - UTTAR PRADESH

36 UTTARAKHAND

36.1 LATENT DEMAND BY YEAR - UTTARAKHAND36.2 CITIES SORTED BY RANK - UTTARAKHAND36.3 CITIES SORTED BY DISTRICT - UTTARAKHAND

37 WEST BENGAL

37.1 LATENT DEMAND BY YEAR - WEST BENGAL37.2 CITIES SORTED BY RANK - WEST BENGAL37.3 CITIES SORTED BY DISTRICT - WEST BENGAL



38 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS

38.1 DISCLAIMERS & SAFE HARBOR38.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS



I would like to order

Product name: The 2023-2028 Outlook for Hydroxyurea Sickle Cell Disease Treatments in India Product link: <u>https://marketpublishers.com/r/2BF449B605D9EN.html</u>

Price: US\$ 595.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/2BF449B605D9EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970